Top Ad unit 728 × 90

Breaking News


FDA approves cord-blood therapy

featured image

The US Food and Drug Administration has approved an umbilical cord blood-based therapy for blood-cancer patients requiring a stem cell transplant. Gamida Cell’s Omisirge (omidubicel) is an allogeneic source of hematopoietic stem cells for transplant, particularly in cases where patients have no matched adult bone marrow donors nor peripheral blood-derived stem cells. Gamida Cell uses nicotinamide — vitamin B3 — to expand umbilical cord blood cells in vitro. Nicotinamide upregulates transcription factors important for stem cell renewal and DNA repair and downregulates those that activate cell differentiation. The lab-expanded allogeneic cells have better marrow homing and engraftment potential, resulting in faster hematopoietic recovery, lower risk of infection and overall better clinical outcomes than with current treatments.

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

$29.99 per month

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

About this article

Verify currency and authenticity via CrossMark

Cite this article

FDA approves cord-blood therapy.
Nat Biotechnol 41, 589 (2023).

Download citation

Read More

FDA approves cord-blood therapy Reviewed by RP on May 17, 2023 Rating: 5

No comments:

Contact Form


Email *

Message *

Powered by Blogger.